Patterns of antiseizure medication use in pregnant women with epilepsy: a 24-year observation in Poland
, 23
Abstract
Aim of study. The aim of this study was to examine trends in the usage of antiseizure medications (ASM) in pregnant women with epilepsy (WWE) in Poland across 24 years.
Clinical rationale for study. Most WWE continue ASM treatment during pregnancy. Over recent decades, third-generation ASMs with different safety profiles have become available. Understanding the long-term trends could provide valuable information for improving clinical practice guidelines.
Material and methods. The study is based on prospectively collected data from an institutional database of a tertiary epilepsy centre between 2000 and 2024. Data on ASM use during pregnancy was recorded at conception and each trimester. Trends in ASM use in monotherapy and polytherapy were analysed. The study included 1,454 completed pregnancies with a known outcome and a mean maternal age of 28.99 years.
Results. WWE were exposed to 19 different ASMs in monotherapy or polytherapy. Lamotrigine (LTG), valproate (VPA), carbamazepine (CBZ) and levetiracetam (LEV) accounted for 82% of all ASMs. Between 2000 and 2024, there was a statistically significant decrease in the usage of CBZ (Exp(B) = 0.92; p < 0.001; 8% annually) and of VPA (Exp(B) = 0.95; p = 0.005, 5% annually) and an increase in the use of LTG (Exp(B) = 1.03; p = 0.086; 3% annually) and of LEV (Exp(B) = 1.19; p < 0.001; 19% annually). More than two-thirds of the women were on monotherapy, both at conception and throughout pregnancy. WWE not exposed to ASMs accounted for 13.9% at conception and 10.5% in all trimesters. There was a significant increase in the number of women receiving polytherapy across all trimesters over time (Exp(B) = 1.02; p = 0.052; 2% annually) and a decrease in untreated women across all trimesters over time (Exp(B) = 0.97; p = 0.033; 3% annually). The mode of treatment at conception did not change statistically over time.
Conclusions/clinical implications. The use of specific ASMs h as c hanged s ignificantly in th e 21 st ce ntury, wi th a no table decrease in the usage of CBZ and VPA in favour of LEV and LTG. There is an increasing trend towards polytherapy across all trimesters, but not at the conception point.
Keywords: women with epilepsyanti-seizure medicationpregnancydrug utilisation trend
References
- Herzog AG, Mandle HB, Fowler KM, et al. Predictors of unintended pregnancy in women with epilepsy. Neurology. 2017; 88(8): 728–733.
- Johnson EL, Burke AE, Wang A, et al. Unintended pregnancy, prenatal care, newborn outcomes, and breastfeeding in women with epilepsy. Neurology. 2018; 91(11): e1031–e1039.
- Gunasekera CL, Sirven JI, Feyissa AM. The evolution of antiseizure medication therapy selection in adults: Is artificial intelligence -assisted antiseizure medication selection ready for prime time? J Cent Nerv Syst Dis. 2023; 15: 11795735231209209.
- Hernández-Díaz S, Smith CR, Shen A, et al. North American AED Pregnancy Registry, North American AED Pregnancy Registry. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012; 78(21): 1692–1699.
- Campbell E, Kennedy F, Russell A, et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry. 2014; 85(9): 1029–1034.
- Tomson T, Battino D, Bonizzoni E, et al. EURAP Study Group. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018; 17(6): 530–538.
- Meador KJ, Baker GA, Browning N, et al. NEAD Study Group. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol. 2013; 12(3): 244–252.
- Tomson T, Battino D, Bonizzoni E, et al. Declining malformation rates with changed antiepileptic drug prescribing. Neurology. 2019; 93(9).
- Battino D, Tomson T, Bonizzoni E, et al. EURAP Collaborators. Risk of Major Congenital Malformations and Exposure to Antiseizure Medication Monotherapy. JAMA Neurol. 2024; 81(5): 481–489.
- Tomson T, Battino D, Bonizzoni E, et al. EURAP study group. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011; 10(7): 609–617.
- Madley-Dowd P, Rast J, Ahlqvist VH, et al. Trends and patterns of antiseizure medication prescribing during pregnancy between 1995 and 2018 in the United Kingdom: A cohort study. BJOG. 2024; 131(1): 15–25.
- Vajda FJE, Hollingworth S, Graham J, et al. Changing patterns of antiepileptic drug use in pregnant Australian women. Acta Neurol Scand. 2010; 121(2): 89–93.
- Meador KJ, Pennell PB, May RC, et al. MONEAD Investigator Group. Changes in antiepileptic drug-prescribing patterns in pregnant women with epilepsy. Epilepsy Behav. 2018; 84: 10–14.
- Majkowska-Zwolińska B, Jędrzejczak J. The Rate of and Factors Associated with Delivery by Caesarean Section among Women with Epilepsy: Time Trend in a Single-Centre Cohort in Mazovia, Poland. J Clin Med. 2022; 11(9).
- Charlton R, Garne E, Wang H, et al. Antiepileptic drug prescribing before, during and after pregnancy: a study in seven European regions. Pharmacoepidemiol Drug Saf. 2015; 24(11): 1144–1154.
- Cohen JM, Cesta CE, Furu K, et al. Prevalence trends and individual patterns of antiepileptic drug use in pregnancy 2006-2016: A study in the five Nordic countries, United States, and Australia. Pharmacoepidemiol Drug Saf. 2020; 29(8): 913–922.
- Kinney MO, Morrow J, Patterson CC, et al. Changing antiepilepsy drug-prescribing trends in women with epilepsy in the UK and Ireland and the impact on major congenital malformations. J Neurol Neurosurg Psychiatry. 2018; 89(12): 1320–1323.
- Bobo WV, Davis RL, Toh S, et al. Trends in the use of antiepileptic drugs among pregnant women in the US, 2001-2007: a medication exposure in pregnancy risk evaluation program study. Paediatr Perinat Epidemiol. 2012; 26(6): 578–588.
- Shouman W, Delaney JA, Kowalec K, et al. Trends of Utilization of Antiseizure Medications Among Pregnant Women in Manitoba, Canada: A 20-Year Population-Based Study. Front Pharmacol. 2022; 13: 871136.
- Houben E, Te Winkel B, Steegers EAP, et al. Dutch trends in the use of potentially harmful medication during pregnancy. Br J Clin Pharmacol. 2020; 86(12): 2377–2392.
- Toledo M, Mostacci B, Bosak M, et al. Expert opinion: use of valproate in girls and women of childbearing potential with epilepsy: recommendations and alternatives based on a review of the literature and clinical experience-a European perspective. J Neurol. 2020; AOP: 1–14.
- Wójcik K, Kruk M, Koń B, et al. Treatment patterns in women of childbearing age and pregnant women with epilepsy in Poland between the years 2019 and 2022-A nationwide population-based cohort study. Seizure. 2024; 115: 75–80.
- Válóczy R, Fekete I, Horváth L, et al. Comparative analysis of three decades' experience in the management of pregnant women with epilepsy: a real-life scenario. Front Neurol. 2023; 14: 1254214.
- Kikuchi D, Obara T, Miura R, et al. Trends in the prescription of anti-seizure medicines for pregnant women outpatients with epilepsy during 2016-2020 in Japan. Seizure. 2022; 98: 101–104.
- National Institute for Health and Care Excellence. Epilepsies: diagnosis and management clinical guideline [CG137] (updated: 12 May 2021). https://www.nice.org. uk/guidance/cg137/chapter/1-Guidance#women-and-girls-with-epilepsy (09.2024).
- EMA. European Medicines Agency. (2016). https://www.ema.europa.eu/en/homepage (09.2024).
- EMA. Assessment report. Referral under Article 31 of Directive 2001/83/EC: medicinal products containing substances related to valproate.2018. https://www.ema.europa.eu/en/committees/pharmacovigilance-risk-assessment-committee-prac (09.2024).
- Giuliano L, La Neve A, Galimberti CA, et al. Valproate and female patients: Prescribing attitudes of Italian epileptologists. Epilepsy Behav. 2019; 97: 182–186.
- Vajda FJE, O'Brien TJ, Graham J, et al. The outcomes of pregnancy in women with untreated epilepsy. Seizure. 2015; 24: 77–81.
- Hoeltzenbein M, Slimi S, Fietz AK, et al. Increasing use of newer antiseizure medication during pregnancy: An observational study with special focus on lacosamide. Seizure. 2023; 107: 107–113.
